Who Pays My Doctor?

Healthcare provider profile · identity verified

Gerald Maguire, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · SAN JUAN CAPISTRACO, CA · NPI 1144300302

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Gerald Maguire, MD received $493,391.30 in general payments during 2025 across 466 reported records.

E.R. Squibb & Sons, L.L.C. accounted for 30.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 14 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$493,391.30

466 reported records · 10 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $152,366.4530.9%1172025
Neurocrine BioSciences, Inc. Unresolved — no canonical attribution shown $141,964.3828.8%1332025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $73,907.3215.0%712025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $42,915.358.7%492025
Alkermes, Inc. Unresolved — no canonical attribution shown $36,996.717.5%322025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $32,868.376.7%292025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $11,630.662.4%102025
Janssen Pharmaceuticals, Inc Unresolved — no canonical attribution shown $587.140.1%232025
Teva Pharmaceuticals USA, Inc. Unresolved — no canonical attribution shown $129.300.0%12025
Otsuka Pharmaceutical Development & Commercialization, Inc. Unresolved — no canonical attribution shown $25.620.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$356,616.5086
Consulting Fee$53,063.009
Travel and Lodging$41,273.73193
Honoraria$30,714.007
Food and Beverage$11,724.07171

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
INGREZZA
Normalized: ingrezza		 Drug Neurocrine BioSciences, Inc. $141,848.05 132 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $118,594.25 101 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $73,907.32 71 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Otsuka America Pharmaceutical, Inc. $42,769.24 47 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $36,929.33 30 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $32,868.37 29 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $11,630.66 10 2025
Source payment records
INVEGA SUSTENNA
Normalized: invega sustenna		 Drug Janssen Pharmaceuticals, Inc $587.14 23 2025
Source payment records
INVEGA TRINZA
Normalized: invega trinza		 Drug Janssen Pharmaceuticals, Inc $543.55 22 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $149.37 4 2025
Source payment records
ABILIFY ASIMTUFII
Normalized: abilify asimtufii		 Drug Otsuka America Pharmaceutical, Inc. $146.11 2 2025
Source payment records
UZEDY
Normalized: uzedy		 Drug Teva Pharmaceuticals USA, Inc. $129.30 1 2025
Source payment records
ABILIFY MAINTENA
Normalized: abilify maintena		 Drug Otsuka America Pharmaceutical, Inc. $120.11 1 2025
Source payment records
ARISTADA INITIO
Normalized: aristada initio		 Drug Alkermes, Inc. $67.38 2 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
GabapentinGabapentin50suppressed
ClonazepamClonazepam31suppressed
LamotrigineLamotrigine30suppressed
Trazodone HclTrazodone Hcl29suppressed
Quetiapine FumarateQuetiapine Fumarate27suppressed
Lurasidone HclLurasidone Hcl24suppressed
PregabalinPregabalin23suppressed
Buspirone HclBuspirone Hcl20suppressed
LorazepamLorazepam19suppressed
OlanzapineOlanzapine18suppressed
Divalproex SodiumDivalproex Sodium13suppressed
Doxepin HclDoxepin Hcl13suppressed
Duloxetine HclDuloxetine Hcl12suppressed
Venlafaxine Hcl ErVenlafaxine Hcl12suppressed
Bupropion Hcl SrBupropion Hcl11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $493,391.30 · 466 records E.R. Squibb & Sons, L.L.C. ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, REXULTI, UZEDY — —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error